Rationale for new treatments aimed at IgE immunomodulation

Keyphrases

• Adverse Effects 33%
• Allergic Asthma 33%
• Allergic Respiratory Diseases 33%
• Anti-IL-13 33%
• Anti-interleukin-1 33%
• Asthma children 33%
• CD23 33%
• Clinical Trials 66%
• CpG Motif 33%
• Current Therapies 33%
• Cytokine Therapy 33%
• Early Humans 33%
• GATA3 33%
• Human Studies 33%
• IgE Production 100%
• IgE-mediated Diseases 66%
• Immunomodulation 100%
• Immunomodulator 66%
• Interferon-α (IFN-α) 66%
• Interleukin-12 (IL-12) 66%
• Interleukin-13 (IL-13) 33%
• Interleukin-4 (IL-4) 100%
• Lymphocytes 33%
• National Conference 33%
• New Therapies 33%
• Omalizumab 66%
• Peer-reviewed Journals 33%
• Peroxisome Proliferator-activated Receptor Agonists 33%
• Plasmid 33%
• Potential Therapy 33%
• Risk-benefit Ratio 33%
• Suplatast Tosilate 33%
• T-bet 33%
• Th-2 33%
• Transcription Factor 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Allergic Asthma 11%
• Clinical Trial 22%
• Cytokine 33%
• Diseases 22%
• Human Study 11%
• Immunoglobulin E 100%
• Immunomodulating Agent 22%
• Immunomodulation 100%
• Interferon 22%
• Interleukin 13 22%
• Interleukin 4 33%
• Lumiliximab 11%
• Omalizumab 22%
• PPAR Agonist 11%
• Respiratory Tract Disease 11%
• Suplatast Tosylate 11%
• Transcription Factor GATA 3 11%
• Transcription Factors 11%